Fortress Biotech, Inc.FBIO
What Fortress Biotech, Inc. does.
Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holding and dividend and royalty revenue streams. Fortress works in concert with our extensive network of key opinion leaders to identify and evaluate promising products and product candidates for potential acquisition. We have executed arrangements in partnership with some of the world’s foremost universities, research institutes and pharmaceutical companies, including City of Hope National Medical Center (“COH” or “City of Hope”), Dana-Farber Cancer Institute, Nationwide Children’s Hospital, Columbia University, the University of Pennsylvania, AstraZeneca plc, Dr. Reddy’s Laboratories, Ltd. (“DRL”), and Sun Pharmaceutical Industries Limited (“Sun Pharma”).
Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress leverages its business, scientific, regulatory, legal and financial expertise to help its subsidiaries and partner companies achieve their goals. Partner and subsidiary companies then assess a broad range of strategic arrangements to accelerate and provide additional funding to support research and development, including joint ventures, partnerships, out-licensings, sales transactions, and public and private financings. To date, three partner companies are publicly-traded, and four subsidiaries have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axsome”), and Sun Pharma.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Net income | -$46.5M | -$64.7M | -$86.6M | -$60.6M | -$46.0M | $6.8M |
| Free cash flow | -$85.6M | -$121.1M | -$182.1M | -$128.3M | -$80.2M | — |
More on FBIO.
- Fortress Biotech, Inc. summary
- Fortress Biotech, Inc. financial statements
- Fortress Biotech, Inc. key metrics
- Fortress Biotech, Inc. health scores and style box
- Fortress Biotech, Inc. earnings
- Fortress Biotech, Inc. dividends
- Fortress Biotech, Inc. valuation
- Fortress Biotech, Inc. ownership and insiders
- Fortress Biotech, Inc. peers
Figures from Fortress Biotech, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.